SHENGDA BIO-PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 53.34 million yuan, a year-on-year increase of 146.04%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, SHENGDA BIO-PHARM disclosed its third-quarter report for 2025. The company achieved revenue of 621 million yuan in the first three quarters, a year-on-year increase of 2.04%; net profit attributable to the parent company was 53.34 million yuan, a year-on-year increase of 146.04%; net profit excluding non-recurring gains and losses was 47.49 million yuan, a year-on-year increase of 393.96%; basic earnings per share were 0.30 yuan
According to the Zhitong Finance APP, SHENGDA BIO-PHARM (603079.SH) disclosed its third-quarter report for 2025. The company achieved revenue of 621 million yuan in the first three quarters, a year-on-year increase of 2.04%; the net profit attributable to shareholders was 53.34 million yuan, a year-on-year increase of 146.04%; the net profit excluding non-recurring items was 47.49 million yuan, a year-on-year increase of 393.96%; and the basic earnings per share were 0.30 yuan